Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus MIRADON.
LIQUAEMIN LOCK FLUSH vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category C
Category C
Anticoagulant
Anticoagulant